TY - JOUR AU - Faragó, Anna AU - Zvara, Ágnes AU - Tiszlavicz, László AU - Hunyadi-Gulyás Éva, Csilla AU - Darula, Zsuzsanna AU - Hegedűs, Zoltán AU - Szabó, Enikő AU - Surguta, Sára Eszter AU - Tóvári, József AU - Puskás, László AU - Szebeni, Gábor TI - Lectin-Based Immunophenotyping and Whole Proteomic Profiling of CT-26 Colon Carcinoma Murine Model. JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 25 PY - 2024 IS - 7 PG - 21 SN - 1661-6596 DO - 10.3390/ijms25074022 UR - https://m2.mtmt.hu/api/publication/34790193 ID - 34790193 N1 - * Megosztott szerzőség AB - A murine colorectal carcinoma (CRC) model was established. CT26 colon carcinoma cells were injected into BALB/c mice's spleen to study the primary tumor and the mechanisms of cell spread of colon cancer to the liver. The CRC was verified by the immunohistochemistry of Pan Cytokeratin and Vimentin expression. Immunophenotyping of leukocytes isolated from CRC-bearing BALB/c mice or healthy controls, such as CD19+ B cells, CD11+ myeloid cells, and CD3+ T cells, was carried out using fluorochrome-labeled lectins. The binding of six lectins to white blood cells, such as galectin-1 (Gal1), siglec-1 (Sig1), Sambucus nigra lectin (SNA), Aleuria aurantia lectin (AAL), Phytolacca americana lectin (PWM), and galectin-3 (Gal3), was assayed. Flow cytometric analysis of the splenocytes revealed the increased binding of SNA, and AAL to CD3 + T cells and CD11b myeloid cells; and increased siglec-1 and AAL binding to CD19 B cells of the tumor-bearing mice. The whole proteomic analysis of the established CRC-bearing liver and spleen versus healthy tissues identified differentially expressed proteins, characteristic of the primary or secondary CRC tissues. KEGG Gene Ontology bioinformatic analysis delineated the established murine CRC characteristic protein interaction networks, biological pathways, and cellular processes involved in CRC. Galectin-1 and S100A4 were identified as upregulated proteins in the primary and secondary CT26 tumor tissues, and these were previously reported to contribute to the poor prognosis of CRC patients. Modelling the development of liver colonization of CRC by the injection of CT26 cells into the spleen may facilitate the understanding of carcinogenesis in human CRC and contribute to the development of novel therapeutic strategies. LA - English DB - MTMT ER - TY - JOUR AU - Gémes, Nikolett AU - Balog, József Ágoston AU - Neuperger, Patricia AU - Schlegl, Erzsébet AU - Barta, Imre AU - Fillinger, János AU - Antus, Balázs AU - Zvara, Ágnes AU - Hegedűs, Zoltán AU - Czimmerer, Zsolt AU - Manczinger, Máté AU - Balogh, Gergő Mihály AU - Tóvári, József AU - Puskás, László AU - Szebeni, Gábor TI - Single-cell immunophenotyping revealed the association of CD4+ central and CD4+ effector memory T cells linking exacerbating chronic obstructive pulmonary disease and NSCLC. JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 14 PY - 2023 PG - 16 SN - 1664-3224 DO - 10.3389/fimmu.2023.1297577 UR - https://m2.mtmt.hu/api/publication/34486293 ID - 34486293 N1 - * Megosztott szerzőség AB - Tobacco smoking generates airway inflammation in chronic obstructive pulmonary disease (COPD), and its involvement in the development of lung cancer is still among the leading causes of early death. Therefore, we aimed to have a better understanding of the disbalance in immunoregulation in chronic inflammatory conditions in smoker subjects with stable COPD (stCOPD), exacerbating COPD (exCOPD), or non-small cell lung cancer (NSCLC).Smoker controls without chronic illness were recruited as controls. Through extensive mapping of single cells, surface receptor quantification was achieved by single-cell mass cytometry (CyTOF) with 29 antibodies. The CyTOF characterized 14 main immune subsets such as CD4+, CD8+, CD4+/CD8+, CD4-/CD8-, and γ/δ T cells and other subsets such as CD4+ or CD8+ NKT cells, NK cells, B cells, plasmablasts, monocytes, CD11cdim, mDCs, and pDCs. The CD4+ central memory (CM) T cells (CD4+/CD45RA-/CD45RO+/CD197+) and CD4+ effector memory (EM) T cells (CD4+/CD45RA-/CD45RO+/CD197-) were FACS-sorted for RNA-Seq analysis. Plasma samples were assayed by Luminex MAGPIX® for the quantitative measurement of 17 soluble immuno-oncology mediators (BTLA, CD28, CD80, CD27, CD40, CD86, CTLA-4, GITR, GITRL, HVEM, ICOS, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, TLR-2) in the four studied groups.Our focus was on T-cell-dependent differences in COPD and NSCLC, where peripheral CD4+ central memory and CD4+ effector memory cells showed a significant reduction in exCOPD and CD4+ CM showed elevation in NSCLC. The transcriptome analysis delineated a perfect correlation of differentially expressed genes between exacerbating COPD and NSCLC-derived peripheral CD4+ CM or CD4+ EM cells. The measurement of 17 immuno-oncology soluble mediators revealed a disease-associated phenotype in the peripheral blood of stCOPD, exCOPD, and NSCLC patients.The applied single-cell mass cytometry, the whole transcriptome profiling of peripheral CD4+ memory cells, and the quantification of 17 plasma mediators provided complex data that may contribute to the understanding of the disbalance in immune homeostasis generated or sustained by tobacco smoking in COPD and NSCLC. LA - English DB - MTMT ER - TY - JOUR AU - Neuperger, Patricia AU - Szalontai, Klára Margit AU - Gémes, Nikolett AU - Balog, József Ágoston AU - Tiszlavicz, László AU - Furák, József AU - Lázár, György ifj AU - Puskás, László AU - Szebeni, Gábor TI - Single-cell mass cytometric analysis of peripheral immunity and multiplex plasma marker profiling of non-small cell lung cancer patients receiving PD-1 targeting immune checkpoint inhibitors in comparison with platinum-based chemotherapy JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 14 PY - 2023 PG - 14 SN - 1664-3224 DO - 10.3389/fimmu.2023.1243233 UR - https://m2.mtmt.hu/api/publication/34199166 ID - 34199166 N1 - Laboratory of Functional Genomics, HUN-REN Biological Research Centre, Szeged, Hungary PhD School in Biology, University of Szeged, Szeged, Hungary Csongrád County Hospital of Chest Diseases, Deszk, Hungary Department of Pathology, University of Szeged, Szeged, Hungary Department of Surgery, University of Szeged, Szeged, Hungary Avicor Ltd, Szeged, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary CS-Smartlab Devices Ltd, Kozármisleny, Hungary Export Date: 7 November 2023 Correspondence Address: Puskás, L.G.; Laboratory of Functional Genomics, Hungary; email: laszlo@avidinbiotech.com Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Hungary; email: szebeni.gabor@brc.hu Funding details: Magyar Tudományos Akadémia, MTA, BO/00582/22/8, ÚNKP-23-5 -SZTE-694 Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFI Funding details: Nemzeti Kutatási, Fejlesztési és Innovaciós Alap, NKFIA, C1764415 Funding details: Innovációs és Technológiai Minisztérium Funding details: National Research, Development and Innovation Office Funding text 1: This research was funded by the 2020‐1.1.6‐JÖVŐ−2021‐00003 and 142877 FK22, KFI_16-1-2017-0105 grant from the National Research, Development, and Innovation Office (NKFI), Hungary. This work was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8 (GS) and by the by the ÚNKP-23-5 -SZTE-694 New National Excellence Program of the Ministry for Innovation and Technology (GS). This manuscript was supported by the KDP-2021 Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund for NG (C1764415). LA - English DB - MTMT ER - TY - CHAP AU - Börzsei, Denise AU - Nagyné Hoffmann, Alexandra AU - Kiss, Viktória AU - Sugár, Anna AU - Neuperger, Patrícia AU - Szebeni, Gábor AU - Bagyánszki, Mária AU - Barta, Bence Pál AU - Almási, Nikoletta AU - Veszelka, Médea AU - Török, Szilvia AU - Varga, Csaba AU - Szabó, Renáta ED - Hagymási, Krisztina ED - Janda, Tibor ED - Pál, Magda ED - Poór, Péter ED - Szalai, Gabriella TI - A PCOS gyulladásos hátterének vizsgálata és terápiás megközelítése T2 - A Magyar Szabadgyökkutató Társaság XII. Kongresszusa PB - Agrártudományi Kutatóközpont, Mezőgazdasági Intézet CY - Martonvásár SN - 9786156203021 PY - 2023 SP - 16 EP - 16 PG - 1 UR - https://m2.mtmt.hu/api/publication/34136606 ID - 34136606 LA - English DB - MTMT ER - TY - JOUR AU - Senobar Tahaei, Seyyed Ashkan AU - Kulmány, Ágnes Erika AU - Minorics, Renáta AU - Kiss, Anita AU - Szabó, Zoltán AU - Germán, Péter AU - Szebeni, Gábor AU - Gémes, Nikolett AU - Mernyák, Erzsébet AU - Zupkó, István TI - Antiproliferative and Antimetastatic Properties of 16-Azidomethyl Substituted 3-O-Benzyl Estrone Analogs JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 24 PY - 2023 IS - 18 PG - 16 SN - 1661-6596 DO - 10.3390/ijms241813749 UR - https://m2.mtmt.hu/api/publication/34131836 ID - 34131836 N1 - Funding Agency and Grant Number: The authors thank Dora Bokor, PharmD, for proofreading the manuscript. Funding text: The authors thank Dora Bokor, PharmD, for proofreading the manuscript. AB - Four diastereomers of 16-azidomethyl substituted 3-O-benzyl estradiol (1–4) and their two estrone analogs (16AABE and 16BABE) were tested for their antiproliferative properties against human gynecological cancer cell lines. The estrones were selected for additional experiments based on their outstanding cell growth-inhibiting activities. Both compounds increased hypodiploid populations of breast cancer cells, and 16AABE elicited cell cycle disturbance as evidenced by flow cytometry. The two analogs substantially increased the rate of tubulin polymerization in vitro. 16AABE and 16BABE inhibited breast cancer cells’ migration and invasive ability, as evidenced by wound healing and Boyden chamber assays. Since both estrone analogs exerted remarkable estrogenic activities, as documented by a luciferase reporter gene assay, they can be considered as promising drug candidates for hormone-independent malignancies. LA - English DB - MTMT ER - TY - JOUR AU - Kiss, Tamás AU - Mir, Mohd Yaqub AU - Stefancsik, Gergely AU - Ganbat, Gantulga AU - Askarova, Aruzhan AU - Monostori, Éva AU - Dulka, Karolina AU - Szebeni, Gábor AU - Nyúl-Tóth, Ádám AU - Csiszar, Anna AU - Légrádi, Ádám TI - Galectin-1 as a marker for microglia activation in the aging brain JF - BRAIN RESEARCH J2 - BRAIN RES VL - 1818 PY - 2023 PG - 13 SN - 0006-8993 DO - 10.1016/j.brainres.2023.148517 UR - https://m2.mtmt.hu/api/publication/34093747 ID - 34093747 N1 - Funding Agency and Grant Number: American Heart Association [GINOP-2.3.2-15-2016-00034, 142877 FK22]; National Research, Development, and Innovation Office (NKFI) , Hungary [AHA834339]; Ministry for Innovation and Technology from the National Research, Development and Innovation Fund; American Heart Association; Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences; [EFOP-3.6.1-16-2016-00008]; [2020-1.1.6-JOVO-2021-00003]; [UNKP-22-5-SZTE-535]; [BO/00582/22/8] Funding text: This work was supported by a grant from EFOP-3.6.1-16-2016-00008 and GINOP-2.3.2-15-2016-00034 grants. ANyT was supported by American Heart Association (AHA834339) . (The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript) . This research was funded by the 2020-1.1.6-JOVO-2021-00003 and 142877 FK22, grant from the National Research, Development, and Innovation Office (NKFI) , Hungary. This work was supported by the UNKP-22-5-SZTE-535 New National Excellence Program (GJS) of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund. This work was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8 (GJS) . AB - Microglia cells, the immune cells residing in the brain, express immune regulatory molecules that have a central role in the manifestation of age-related brain characteristics. Our hypothesis suggests that galectin-1, an anti-inflammatory member of the beta-galactoside-binding lectin family, regulates microglia and neuroinflammation in the aging brain. Through our in-silico analysis, we discovered a subcluster of microglia in the aged mouse brain that exhibited increased expression of galectin-1 mRNA. In our Western blotting experiments, we observed a decrease in galectin-1 protein content in our rat primary cortical cultures over time. Additionally, we found that the presence of lipopolysaccharide, an immune activator, significantly increased the expression of galectin-1 protein in microglial cells. Utilizing flow cytometry, we determined that a portion of the galectin-1 protein was localized on the surface of the microglial cells. As cultivation time increased, we observed a decrease in the expression of activation-coupled molecules in microglial cells, indicating cellular exhaustion. In our mixed rat primary cortical cell cultures, we noted a transition of amoeboid microglial cells labeled with OX42(CD11b/c) to a ramified, branched phenotype during extended cultivation, accompanied by a complete disappearance of galectin-1 expression. By analyzing the transcriptome of a distinct microglial subpopulation in an animal model of aging, we established a correlation between chronological aging and galectin-1 expression. Furthermore, our in vitro study demonstrated that galectin-1 expression is associated with the functional activation state of microglial cells exhibiting specific amoeboid morphological characteristics. Based on our findings, we identify galectin-1 as a marker for microglia activation in the context of aging. LA - English DB - MTMT ER - TY - JOUR AU - Szebeni, Gábor AU - Alföldi, Róbert AU - Nagy, Lajos I. AU - Neuperger, Patricia AU - Gémes, Nikolett AU - Balog, József Ágoston AU - Tiszlavicz, László AU - Puskás, László TI - Introduction of an Ultraviolet C-Irradiated 4T1 Murine Breast Cancer Whole-Cell Vaccine Model JF - VACCINES (BASEL) J2 - VACCINES-BASEL VL - 11 PY - 2023 IS - 7 PG - 18 SN - 2076-393X DO - 10.3390/vaccines11071254 UR - https://m2.mtmt.hu/api/publication/34076543 ID - 34076543 N1 - Laboratory of Functional Genomics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary CS-Smartlab Devices Ltd., Ady E. u. 14, Kozármisleny, H7761, Hungary AstridBio Technologies Ltd., Wimmer Fülöp utca 1, Szeged, H6728, Hungary Avidin Ltd, Alsó Kikötő sor 11/D, Szeged, H6726, Hungary Department of Pathology, University of Szeged, Állomás u. 2, Szeged, H6725, Hungary Export Date: 20 October 2023 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Correspondence Address: Puskás, L.G.; Laboratory of Functional Genomics, Temesvári krt. 62, Hungary; email: laszlo@avidinbiotech.com Chemicals/CAS: cyclophosphamide, 50-18-0, 6055-19-2; immunoglobulin G, 97794-27-9, 308067-58-5; interleukin 2, 85898-30-2; propidium iodide, 25535-16-4; resazurin, 550-82-3; streptomycin, 57-92-1 Manufacturers: Thermo, United States Funding details: Magyar Tudományos Akadémia, MTA, BO/00582/22/8 Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH Funding details: National Research, Development and Innovation Office Funding text 1: This research was funded by the 2020-1.1.6-JÖVŐ−2021-00003 and 142877 FK22 grants from the National Research, Development, and Innovation Office (NKFI), Hungary. This work was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8 (GJS). AB - The advent of immunotherapy has revolutionized cancer treatments. However, the application of immune checkpoint inhibitors may entail severe side effects, with the risk of therapeutic resistance. The generation of chimeric antigen receptor (CAR) T-cells or CAR-NK cells requires specialized molecular laboratories, is costly, and is difficult to adapt to the rapidly growing number of cancer patients. To provide a simpler but effective immune therapy, a whole-cell tumor vaccine protocol was established based on ultraviolet C (UCV)-irradiated 4T1 triple-negative breast cancer cells. The apoptosis of tumor cells after UVC irradiation was verified using resazurin and Annexin V/propidium iodide flow cytometric assays. Protective immunity was achieved in immunized BALB/c mice, showing partial remission. Adoptive transfer of splenocytes or plasma from the mice in remission showed a protective effect in the naive BALB/c mice that received a living 4T1 tumor cell injection. 4T1-specific IgG antibodies were recorded in the plasma of the mice following immunization with the whole-cell vaccine. Interleukin-2 (IL-2) and oligonucleotide 2006 (ODN2006) adjuvants were used for the transfer of splenocytes from C57BL/6 mice into cyclophosphamide-treated BALB/c mice, resulting in prolonged survival, reduced tumor growth, and remission in 33% of the cases, without the development of the graft-versus-host disease. Our approach offers a simple, cost-effective whole-cell vaccine protocol that can be administered to immunocompetent healthy organisms. The plasma or the adoptive transfer of HLA-matching immunized donor-derived leukocytes could be used as an immune cell therapy for cancer patients. LA - English DB - MTMT ER - TY - JOUR AU - Szabó, Enikő AU - Modok, Szabolcs AU - Rónaszéki, Benedek AU - Faragó, Anna AU - Gémes, Nikolett AU - Nagy, Lajos I. AU - Hackler, László AU - Farkas, Katalin AU - Neuperger, Patricia AU - Balog, József Ágoston AU - Balog, Attila AU - Puskás, László AU - Szebeni, Gábor TI - Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 JF - FRONTIERS IN MEDICINE J2 - FRONT MED VL - 10 PY - 2023 PG - 11 SN - 2296-858X DO - 10.3389/fmed.2023.1176168 UR - https://m2.mtmt.hu/api/publication/34069256 ID - 34069256 N1 - Funding Agency and Grant Number: National Research, Development, and Innovation Office (NKFI), Hungary [2020-1.1.6-JOVO-2021-00003, 142877 FK22, KFI_16-1-2017-0105]; KDP-2021 Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund [C1764415]; Jnos Bolyai Research Scholarship of the Hungarian Academy of Sciences [BO/00582/22/8]; Ministry of Culture and Innovation; New National Excellence Program [NTP-NFTOE-21-B-0164] Funding text: This research was funded by the 2020-1.1.6-JOEVO-2021-00003 and 142877 FK22, KFI_16-1-2017-0105 grant from the National Research, Development, and Innovation Office (NKFI), Hungary. This work was supported by the UNKP-22-5-SZTE-535 New National Excellence Program for GS, and by the KDP-2021 Program for NG (C1764415) of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund. This work was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8 (GS). This manuscript was prepared with the professional support of SZTE AOK-KKA Hetenyi Geza Scholarship_5S726 (AB). This manuscript was prepared with the support of the National Young Talent Scholarship for ES (NTP-NFTOE-21-B-0164) by the Ministry of Culture and Innovation. LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Viktória AU - Mounir, Raji AU - Szebeni, Gábor AU - Szakonyi, Zsolt AU - Gémes, Nikolett AU - Minorics, Renáta AU - Germán, Péter AU - Zupkó, István TI - Investigation of Anticancer Properties of Monoterpene-Aminopyrimidine Hybrids on A2780 Ovarian Cancer Cells JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 24 PY - 2023 IS - 13 PG - 17 SN - 1661-6596 DO - 10.3390/ijms241310581 UR - https://m2.mtmt.hu/api/publication/34034428 ID - 34034428 N1 - Institute of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, H-6720, Hungary Institute of Pharmaceutical Chemistry, University of Szeged, Szeged, H-6720, Hungary Laboratory of Functional Genomics, Eötvös Loránd Research Network Biological Research Centre, Institute of Genetics, Szeged, H-6726, Hungary Interdisciplinary Centre of Natural Products, University of Szeged, Szeged, H-6720, Hungary Export Date: 24 July 2023 Correspondence Address: Zupkó, I.; Institute of Pharmacodynamics and Biopharmacy, Hungary; email: zupko.istvan@szte.hu Funding details: Magyar Tudományos Akadémia, MTA, BO/00582/22/8, TKP2021-EGA-32 Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH, 142877 FK22, 2020-1.1.6-JÖVŐ-2021-00003, K 143690 Funding details: Nemzeti Kutatási, Fejlesztési és Innovaciós Alap, NKFIA Funding text 1: This research was funded by the Hungarian Research Foundation (NKFI), grant numbers K 143690, 142877 FK22, and 2020-1.1.6-JÖVŐ-2021-00003, as well as by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8 (G.J.S.). TKP2021-EGA-32 was implemented with support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme. AB - The present study aimed to characterize the antiproliferative and antimetastatic properties of two recently synthesized monoterpene-aminopyrimidine hybrids (1 and 2) on A2780 ovary cancer cells. Both agents exerted a more pronounced cell growth inhibitory action than the reference agent cisplatin, as determined by the MTT assay. Tumor selectivity was assessed using non-cancerous fibroblast cells. Hybrids 1 and 2 induced changes in cell morphology and membrane integrity in A2780 cells, as evidenced by Hoechst 33258–propidium iodide fluorescent staining. Cell cycle analysis by flow cytometry revealed substantial changes in the distribution of A2780 ovarian cancer cells, with an increased rate in the subG1 and G2/M phases, at the expense of the G1 cell population. Moreover, the tested molecules accelerated tubulin polymerization in a cell-free in vitro system. The antimetastatic properties of both tested compounds were investigated by wound healing and Boyden chamber assays after 24 and 48 h of incubation. Treatment with 1 and 2 resulted in time- and concentration-dependent inhibition of migration and invasion of A2780 cancer cells. These results support that the tested agents may be worth of further investigation as promising anticancer drug candidates. LA - English DB - MTMT ER - TY - JOUR AU - Germán, P. AU - Veréb, Zoltán AU - Bozó, Renáta AU - Flink, Lili Borbála AU - Erdei, Lilla AU - Groma, Gergely AU - Szebeni, Gábor AU - Csörgő Sándorné Bata, Zsuzsanna AU - Kemény, Lajos AU - Németh, István Balázs TI - Morphologic variants of cell cannibalism in the spontaneous human melanoma-fibroblast hybrids using high-content fluorescent microscope imaging JF - JOURNAL OF INVESTIGATIVE DERMATOLOGY J2 - J INVEST DERMATOL VL - 143 PY - 2023 IS - Suppl. 5 SP - S219 EP - S219 PG - 1 SN - 0022-202X DO - 10.1016/j.jid.2023.03.1290 UR - https://m2.mtmt.hu/api/publication/33927401 ID - 33927401 N1 - HCEMM-USZ Skin Research Group, Szeged, Hungary LA - English DB - MTMT ER -